Focusing on a genetically engineered mouse model, cultured spheres derived from APC/KRAS/PTEN intestinal tumours were largely insensitive to BEZ235 as a single agent; however, they responded to sequential treatment with bortezomib followed by BEZ235 (Fig. 10a). Here, KRAS is linked to intestinal neoplasm.